Targeting fibrosis and steatohepatitis through the metabolism – results from the ESSENCE trial
Open Access
- 1 August 2025
- journal article
- Published by Elsevier in JHEP Reports
- Vol. 7 (9) , 101492
Abstract
No abstract availableFunding Information
- Saarland University
This publication has 14 references indexed in Scilit:
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated SteatohepatitisNew England Journal of Medicine, 2025
- Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE TrialAlimentary Pharmacology & Therapeutics, 2024
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver FibrosisNew England Journal of Medicine, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialThe Lancet Gastroenterology & Hepatology, 2023
- The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic reviewHepatology, 2023
- NASH: regulatory considerations for clinical drug development and U.S. FDA approvalActa Pharmacologica Sinica, 2022
- Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver DiseaseNew England Journal of Medicine, 2021
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2021
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016